Evotec SE
Evotec launches beLAB2122 , translating academic innovation from leading German life science region in collaboration with Bristol Myers Squibb
DGAP-News: Evotec SE / Key word(s): Miscellaneous
Evotec launches beLAB2122 , translating academic innovation from leading German life science region in collaboration with Bristol Myers Squibb
13.04.2021 / 07:30
beLAB2122 LEVERAGES ACADEMIC INNOVATION FROM THE RHINE-MAIN-NECKAR REGION OF GERMANY
EVOTEC PROVIDES ITS ALL-MODALITY PLATFORM TO VALIDATE FIRST-IN-CLASS THERAPEUTIC PROJECTS FROM THE UNIVERSITIES OF FRANKFURT, HEIDELBERG AND TÜBINGEN AS WELL AS FROM THE EMBL AND THE DKFZ
BRISTOL MYERS SQUIBB TO PROVIDE FUNDING AND COMMERCIAL PERSPECTIVES FOR ACADEMIC ASSETS DEVELOPED BY beLAB2122
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
DGAP-News: Dermapharm Holding SE / Key word(s): Annual Results
Dermapharm forecasts exceptionally strong growth for 2021 and confirms preliminary figures
13.04.2021 / 07:30
Dermapharm forecasts exceptionally strong growth for 2021 and confirms preliminary figures
» Revenue and earnings up due to organic growth and successful acquisitions
» Vaccine production to commence in May 2021 at Allergopharma s site in Reinbek
» Consolidated revenue to grow by 24 % - 26 % in 2021
» Consolidated EBITDA to increase by 45 % - 50 % in 2021
» Dividend proposal of EUR 0.88 per share for 2020
Grünwald, 13 April 2021 - Dermapharm Holding SE ( Dermapharm ), a rapidly growing manufacturer of branded pharmaceuticals for selected therapeutic areas in Germany, today published its full Annual Report 2020. Dermapharm confirms its preliminary consolidated figures (IFRS) for financial year 2020. Both consolidated revenue and consolidated earnings continue on their clear growth trajectory. Gro